Synthesis and evaluation of (17α,20Z)-21-(4-substituted-phenyl)-19- norpregna-1,3,5(10),20-tetraene-3,17β-diols as ligands for the estrogen receptor-α hormone binding domain: Comparison with 20E-isomers

Journal of Medicinal Chemistry

Volumn 48, Issue 13, 2005, Pages 4300-4311

  Hanson, Robert N ^a   Friel, Carolyn J ^a   Dilis, Robert ^a   Hughes, Alun ^b   DeSombre, Eugene R ^b  

^a NORTHEASTERN UNIVERSITY   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(17 ALPHA) 21 (PHENYL) 19 NORPREGNA 1,3,5(10),20 TETRAENE 3,17 BETA DIOL; (17 ALPHA) 21 [(4 ACETYL)PHENYL] 19 NORPREGNA 1,3,5(10),20 TETRAENE 3,17 BETA DIOL; (17 ALPHA) 21 [(4 AMINO)PHENYL] 19 NORPREGNA 1,3,5(10),20 TETRAENE 3,17 BETA DIOL; (17 ALPHA) 21 [(4 FLUORO)PHENYL] 19 NORPREGNA 1,3,5(10),20 TETRAENE 3,17 BETA DIOL; (17 ALPHA) 21 [(4 HYDROXY)PHENYL] 19 NORPREGNA 1,3,5(10),20 TETRAENE 3,17 BETA DIOL; (17 ALPHA) 21 [(4 METHOXY)PHENYL] 19 NORPREGNA 1,3,5(10),20 TETRAENE 3,17 BETA DIOL; ESTRADIOL DERIVATIVE; ESTROGEN RECEPTOR ALPHA; LIGAND; UNCLASSIFIED DRUG; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS; PREGNANE DERIVATIVE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ARTICLE; DRUG BINDING; DRUG EFFECT; DRUG MECHANISM; DRUG SYNTHESIS; HORMONE BINDING; HORMONE RECEPTOR INTERACTION; LIGAND BINDING; MOLECULAR MODEL; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION; ANIMAL; BINDING SITE; CELL LINE; CHEMICAL STRUCTURE; CHEMISTRY; CONFORMATION; ISOMERISM; PHYSIOLOGY; PROTEIN BINDING; SYNTHESIS;

ANIMALS; BINDING SITES; CELL LINE; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR MODULATORS; INDICATORS AND REAGENTS; ISOMERISM; LIGANDS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MOLECULAR STRUCTURE; NORPREGNATRIENES; PROTEIN BINDING;

EID: 21244440739     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm040157s     Document Type: Article

References (56)

1. Evans, R. M. The steroid and thyroid hormone receptor superfamily. Science 1988, 240, 889-895.
2. Tsai, M.-J.; O'Malley, B. W. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu. Rev. Biochem. 1994, 63, 451-486.
3. Nilsson, S.; Gustafsson, J.-A. Biological role of estrogen and estrogen receptors. Crit. Rev. Biochem. Mol. Biol. 2002, 37, 1-28.
4. Hart, L. L.; Davie, J. R. The estrogen receptor: more than the average transcription factor. Biochem. Cell Biol. 2002, 80, 335-341.
5. Pike, A. C. W.; Brzozowski, A. M.; Hubbard, R. E. A structural biologist's view of the oestrogen receptor. J. Steroid Biochem. Mol. Biol. 2000, 74, 261-268.
6. Katzenellenbogen, B. S.; Choi, I.; Delage-Mourroux, R.; Ediger, T. R.; Martini, P. G. V.; Montano, M.; Sun, J.; Weis, K.; Katzenellenbogen, J. A. Molecular mechanisms of estrogen action: selectve ligands and receptor pharmacology. J. Steroid Biochem. Mol. Biol. 2000, 74, 279-285.
7. McDonnell, D. P.; Dana, S. L.; Hoener, P. A.; Lieberman, B. A.; Imhof, M. O.; Stein, R. B. Cellular mechanisms which distinguish between hormone- and antihormone-activated estrogen receptor. Ann. N.Y. Acad. Sci. 2001, 949, 121-137.
8. Dutertre, M.; Smith, C. L. Molecular mechanisms of selective estrogen receptor modulator (SERM) action. J. Pharmacol. Exp. Ther. 2000, 295, 431-437.
9. Krishnan, V.; Heath, H.; Bryant, H. U. Mechanism of action of estrogens and selective estrogen receptor modulators. Vitam. Horm. 2001, 60, 123-147.
10. Katzenellenbogen, B. S.; Sun, J.; Harrington, W. R.; Kraichely, D. M.; Ganessunker, D.; Katzenellenbogen, J. A. Structure-function relationships in estrogen receptors and the characterization of novel selective estrogen receptor modulators with unique pharmacological profiles. Ann. N.Y. Acad. Sci. 2001, 949, 6-15.
11. Leclercq, G. Molecular forms of the estrogen receptor in breast cancer. J. Steroid Biochem. Mol. Biol. 2002, 80, 259-272.
12. Miner, J. N.; Tyree, C. M. Drug discovery and the intracellular receptor family. Vitam. Horm. 2001, 62, 253-280.
13. Karamouzis, M. V.; Gorgoulis, V. G.; Papavassiliou, A. G. Transcription factors and neoplasia: vistas in novel drug design. Clin. Cancer Res. 2002, 8, 949-961.
14. Johnston, S. R. D.; Riddle, S.; Haynes, B. P.; Hern, R. A.; Smith, I. E.; Jarman, M.; Dowsett, M. The novel anti-estrogen iodoxifene inhibits the growth of human cancer xenografts and reduces the frequency of acquired anti-estrogen resistance. Br. J. Cancer 1997, 75, 804-809.
15. Jones, C. D.; Jevnikar, M. G.; Pike, A. J.; Peters, M. K.; Black, L. J.; Falcone, J. F.; Clemens, J. A. Anti-estrogens. 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]-thien-2-yl][4-[2-(1-piperidinyl)ethoxy] phenyl]methanone hydrochloride LY 156758, a remarkably effective estrogen antagonist with only minimal intrinsic activity. J. Med. Chem. 1984, 27, 1057-1066.
16. Palkowitz, A. D.; Glasebrook, A. L.; Thrasher, K. J.; Hauser, K. L.; Short, L. L.; Phillips, D. L.; Muehl, B. S.; Sato, M.; Shetler, P. K.; Cullinan, G. L.; Pell, T. R.; Bryant, H. U. Discovery and synthesis of [6-hydroxy-3-[4-[2-(1-piperidinyl)-ethoxy]phenoxy]-2-(4-hydroxyphenyl)]benzo[b] thiophene: a novel, highly potent, selective estrogen receptor modulator. J. Med. Chem. 1997, 40, 1407-1416.
17. LaBrie, F.; LaBrie, C.; Belanger, A.; Simard, J.; Gauthier, S.; Luu-The, V.; Merand, Y.; Giguere, V.; Candas, B.; Luo, S.; Martel, C.; Singh, S. M.; Fournier, M.; Coquet, A.; Richard, V.; Charbonneau, R.; Charpanet, G.; Tremblay, A.; Cusan, L.; Villeux, R. EM-652 (SCH 57068), a third generation SERM acting as a pure anti-estrogen in the mammary gland and endometrium. J. Steroid Biochem. Mol. Biol. 1999, 69, 51-84.
18. Greenberger, L. M.; Annablr, T.; Collins, K. I.; Komm, B. S.; Lyttle, C. R.; Miller, C. P.; Satyaswaroop, P. G.; Zhang, Y.; Frost, P. A new anti-estrogen, 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-2-yl-ethoxy-) benzyl]-1H-indol-5-ol hydrochloride (ERA-923), inhibits the growth of tamoxifen-sensitive and -resistant tumors and is devoid of uterotrophic effects in mice and rats. Clin. Cancer Res. 2001, 7, 3166-3177.
19. Meegan, M. J.; Hughes, R. B.; Lloyd, D. G.; Williams, D. C.; Zisterer, D. M. Ethyl side-chain modifications in novel flexible anti-estrogens-design, synthesis and biological efficacy in assay against the MCF-7 breast tumor cell line. Anti-Cancer Drug Des. 2001, 16, 57-69.
20. Weatherman, R. V.; Carroll, D. C.; Scanlan, T. S. Activity of a tamoxifen-raloxifene hybrid ligand for estrogen receptors at an AP-1 site. Bioorg. Med. Chem. Lett. 2001, 11, 3129-3131.
21. Rosati, R. L.; Da Silva, J.; Cameron, K. O.; Thompson, D. D.; Ke, H. Z.; Toler, S. M.; Brown, T. A.; Pan, L. C.; Ebbinghaus, C. F.; Reinhold, A. R.; Elliott, N. C.; Newhouse, B. N.; Tjoa, C. M.; Sweetnam, P. M.; Cole, M. J.; Arriola, M. W.; Gauthier, J. W.; Crawford, D. T.; Nickerson, D. F.; Pine, C. M.; Qi, H.; Simmons, H. A.; Tkalcevic, G. T. Discovery and preclinical pharmacology of a novel, potent, nonsteroidal estrogen receptor agonist/antagonist, CP 336156, a diaryltetrahydronaphthalene. J. Med. Chem. 1998, 41, 2928-2931.
22. Bury, P. S.; Christiansen, L. B.; Jacobsen, P.; Jorgensen, A. S.; Kanstrup, A.; Naerum, L.; Bain, S.; Fledelius, C.; Gissel, B.; Hansen, B. S.; Korsgaard, N.; Thorpe, S. M.; Wasserman, K. Synthesis and pharmacological evaluation of novel cis-3,4-diaryl-hydroxychromanes as high affinity partial agonists for the estrogen receptor. Bioorg. Med. Chem. 2002, 10, 125-145.
23. Levenson, A. S.; MacGregor-Schafer, J. I.; Bentrm, D. J.; Pease, K. M.; Jordan, V. C. Control of the estrogen-like action of tamoxifen-estrogen receptor complex by the surface amino acid at position 351. J. Steroid Biochem. Mol. Biol. 2001, 76, 61-70.
24. Jordan, V. C.; MacGregor-Schafer, J.; Levenson, A. S.; Liu, H.; Pease, K. M.; Simons, L. A.; Zapf, J. W. Molecular classification of estrogens. Cancer Res. 2001, 61, 6619-6623.
25. Napolitano, E.; Fiaschi, R.; Hanson, R. N. Structure-activity relationships of estrogenic ligands. Synthesis and evaluation of (17α,20E/Z)-21-halogenated-19-norpregna-1,3,5(10),20-tetraene-3, 17β-diols. J. Med. Chem. 1991, 34, 2754-2759.
26. Napolitano, E.; Fiaschi, R.; Herman, L. W.; Hanson, R. N. Synthesis and estrogen receptor binding of (17α,20E)- and (17α,20Z)-21-phenylthio- and phenylseleno-19-norpregna-1,3,5(10),20-tetraene-3,17β-diols. Steroids 1996, 61, 384-387.
27. Hanson, R. N.; Herman, L. W.; Fiaschi, R.; Napolitano, E. Stereochemical probes for the estrogen receptor: Synthesis and receptor binding of (17α,20E/Z)-21-phenyl-19-norpregna-1,3,5(10),20-tetraene-3,17β-diols. Steroids 1996, 61, 718-722.
28. Hanson, R. N.; Napolitano, E.; Fiaschi, R. Novel high affinity steroidal estrogenic ligands: Synthesis and receptor binding of 11β-vinyl-17α- E/Z-phenylselenovinyl estradiols. Steroids 1998, 63, 479-483.
29. Hanson, R. N.; Napolitano, E.; Fiaschi, R. Synthesis and evaluation of 11β-substituted-21-chloro/iodo-(17α,20E/Z)-19-norpregna-1,3,5(10), 20-tetraene-3,17β-diols: High affinity ligands for the estrogen receptor. J. Med. Chem. 1998, 41, 4686-4692.
30. McKenna, N. J.; O'Malley, B. W. From ligand to response: generating diversity in nuclear coregulator function. J. Steroid Biochem. Mol. Biol. 2000, 74, 351-356.
31. Connor, C. E.; Norris, J. D.; Broadwater, G.; Willson, T. M.; Gottardis, M. M.; Dewhirst, M. W.; McDonnell, D. P. Circumventing tamoxifen resistance in breast cancers using antiestrogens that induce unique conformational changes in the estrogen receptor. Cancer Res. 2001, 61, 2917-2922.
32. Sathya, G.; Jansen, M. S.; Nagel, S. C.; Cook, C. E.; McDonnell, D. P. Identification and characterization of novel estrogen receptor-β-sparing antiprogestins. Endocrinology 2002, 143, 3071-3082.
33. Liu, H.; Lee, E.-S.; De Los Reyes, A.; Zapf, J. W.; Jordan, V. C. Silencing and reactivation of the selective estrogen receptor modulator-estrogen receptor α complex. Cancer Res. 2001, 61, 3632-3639.
34. Levenson, A. S.; Svoboda, K. M.; Pease, K. M.; Kaiser, S. A.; Chen, B.; Simons, L. A.; Jovanovic, B. D.; Dyck, P. A.; Jordan, V. C. Gene expression profiles with activation of the estrogen receptor á-selective estrogen receptor modulator complex in breast cancer cells expressing wild-type estrogen receptor. Cancer Res. 2002, 62, 4419-4426.
35. Hanson, R. N.; Lee, C. Y.; Friel, C. J.; DeSombre, E. R.; Hughes, A. Evaluation of 17a-(trifluoromethylphenyl)vinyl estradiols as novel estrogen receptor ligands. Steroids 2003, 68, 143-148.
36. Hanson, R. N.; Lee, C. Y.; Friel, C. J.; Dilis, R.; DeSombre, E. R.; Hughes, A. Synthesis and evaluation of (17α,20E)-21-(4-substituted-phenyl) -19-norpregna-1,3,5(10),20-tetraene-3,17/3-diols as probes for the estrogen receptor-α (ERα) hormone binding domain. J. Med. Chem. 2003, 46, 2865-2876.
37. Lebl, T.; Holecek, J.; Dymal, M.; Steinborn, D. Synthesis and characterization and reactivity of 2-functionalized vinylstannanes. J. Organomet. Chem. 2001, 625, 86-94.
38. Lipshutz, B. H.; Keil, R.; Barton, J. C. Preparation of Z-vinylstannanes via hydrozirconation of stannylacetylenes. Tetrahedron Lett. 1992, 33, 5861-5864.
39. Sielstad, D. A.; Carlson, K. E.; Katzenellenbogen, J. A.; Kushner, P. J.; Greene, G. L. Molecular characterization by mass spectrometry of the human estrogen receptor ligand-binding domain expressed in Escherichia coli. Mol. Endocrinol. 1993, 9, 647-658.
40. DeSombre, E. R.; Mease, R. C.; Sanghavi, J.; Singh, T.; Seevers, R. H.; Hughes, A. Estrogen receptor binding affinity and uterotrophic activity of triphenylhaloethylenes. J. Steroid Biochem. 1988, 29, 583-590.
41. Raynaud, J. P.; Ojasoo, T.; Bouton, M. M.; Philibert, D. Receptor binding as a tool in the development of new bioactive steroids. In Drug Design; Ariens, E. J., Ed.; Academic Press: New York, 1979; Vol. VIII, pp 169-214.
42. Eiler, S.; Gangloff, M.; Duclaud, S.; Moras, D.; Ruff, M. Overexpression, purificiation and crystal structure of native ER alpha LBD. Protein Expression Purif. 2001, 20, 165.
43. Littke, A. F.; Fu, G. C. The first general method for Stille cross-couplings of aryl chlorides. Angew. Chem., Int. Ed. 1999, 38, 2411-2416.
44. Littke, A. F.; Fu, G. C. Palladium-catalyzed coupling reactions of aryl chlorides. Angew. Chem., Int. Ed. 2002, 41, 4176-4211.
45. Bapat, A. R.; Frail, D. E. Full-length estrogen receptor α and its ligand-binding domain adopt different conformations upon ligand binding. J. Steroid Biochem. Mol. Biol. 2003, 86, 143-149.
46. Wurtz, J.-M.; Egner, U.; Heinrich, N.; Moras, D.; Mueller-Fahrnow, A. Three-dimensional models of estrogen receptor ligand binding domain complexes, based on related crystal structures and mutational and structure-activity relationships. J. Med. Chem. 1998, 41, 1803-1814.
47. Sippl, W. Receptor-based 3-D QSAR analysis of estrogen receptor ligands-merging the accuracy of receptor-based alignments with the computational efficiency of ligand-based methods. J. Comput.-Aided Mol. Des. 2000, 14, 559-572.
48. Egner, U.; Heinrich, N.; Ruff, M.; Gangloff, M.; Mueller-Fahrnow, A.; Wurtz, J.-M. Different ligands-different receptor conformations: modeling of the hERα-LBD in complexes with agonists and antagonists. Med. Res. Rev. 2001, 21, 523-539.
49. Wolohan, P.; Reichert, D. E. CoMFA and docking study of novel estrogen receptor subtype selective ligands. J. Comput.-Aided Mol. Des. 2003, 17, 313-328.
50. Schipira, M.; Abagyan, R.; Totrov, M. Nuclear hormone receptor targeted virtual screening. J. Med. Chem. 2003, 46, 3045-3059.
51. van Lipzig, M. M. H.; ter Laak, A. M.; Jongejan, A.; Vermeulen, N. P. E.; Wamelink, M.; Geerke, D.; Meerman, J. H. N. Prediction of ligand binding affinity and orientation of xenoestrogens to the estrogen receptor by molecular dynamics simulations and the linear interaction energy method. J. Med. Chem., in press.
52. DeLisle, R. K.; Yu, S.-J.; Nair A. C.; Welsh, W. J. Homology modeling of the estrogen receptor subtype β (ERβ) and calculation of ligand binding affinities. J. Mol. Graphics Modell. 2001, 20, 155-167.
53. 13C shieldings. J. Org. Chem. 2000, 65, 7902-7912.
54. Katzenellenbogen, B. S.; Sun, J.; Harrington, W. R.; Kraichely, D. M.; Ganessunker, D.; Katzenellenbogen, J. A. Structure-function relationships in the estrogen receptors and the characterization of novel selective estrogen receptor modulators with unique pharmacological profiles. Ann. N. Y. Acad. Sci., submitted.
55. Insight II, 97.2 and Discover 2.9.7; MSI Inc.: San Diego, CA.
56. Nair, A. C.; Miertus, S.; Tossi, A.; Romeo, D. A computational study of the resistance of HIV-1 aspartic protease to inhibitors ABT-538 and VX-478 and design of new analogues. Biochem. Biophys. Res. Commun. 1998, 242, 545-551.